Report Sections

See All Reports

  • RNA COVID 19
  • COVID-19 (39) SARS-CoV-2 (39) vaccine (18) Vaccine (14) Safety (11) Coronavirus (10) Immunogenicity (9) SARS-CoV-2 Vaccine (7) Virus Diseases (6) Ad5 (5) COVID-19 Vaccine (5) COVID-19 vaccine (5) vector vaccine (5) BCG (4) Coronavirus Disease 2019 (4) Covid19 (4) coronavirus (4) COVID (3) COVID 19 (3) Coronavirus infection (3) Covid-19 (3) Dose-escalation (3) Messenger RNA (3) Moderna (3) Protection against COVID-19 (3) RNA Vaccine (3) Recombinant vaccine (3) SARS (3) adenoviral vector (3) mRNA-1273 (3) mRNA-1273 vaccine (3) Ad5-nCoV (2) Adenovirus Vector (2) BCG vaccine (2) COVID-19 Prevention (2) COVID19 (2) ChAdOx1 nCov19 (2) Convalescent plasma (2) DNA vaccine (2) Electroporation (2) Health care workers (2) Immunogencity (2) Passive immunization (2) Prevention (2) Reactogenicity (2) SARS-CoV 2 (2) SARS-CoV-2 infection (2) Severe acute respiratory syndrome coronavirus 2 (2) Sputnik V (2) Tolerability (2) Transfusion (2) covid-19 (2) immunogenicity (2) infectious respiratory diseases (2) novel coronavirus (2) sars-cov-2 (2) 2019 novel coronavirus (1) 2019-nCoV (1) 2019-nCoV (mRNA-1273) (1) ACE2 (1) ARDS (1) AT1 (1) AZD1222 vaccine (1) AZD1222 vaccine for COVID-19 Prevention (1) Ad26 (1) Ad26COVS1 (1) Adenovirus V (1) AlloStim (1) Alvelestat (1) Antibodies, Neutralizing (1) Antibodies, viral/blood (1) Antibody (1) BACILLUS CALMETTE-GUÉRIN VACCINATION (1) BBV152 (1) BCG Vaccination (1) BCG Vaccine (1) Bacille Calmette-Guérin (1) Bacillus Calmette-Guerin (1) Bacillus Calmette-Guérin vaccination (1) Blinded (1) CEPI (1) COVID 19 Vaccine (1) COVID 19 Vaccine Arcturus (1) COVID 2019 (1) COVID-1 (1) COVID-19 infection (1) COVID-19 serotherapy (1) COVID-19, Convalescent plasma therapy (1) COVID-19, SARS-CoV-2 Vaccine (1) COVID-19, Vaccine (1) COVID-2019 (1) COVID19 ( Corona Virus Disease -2019) (1) Clinical trials (1) Coronavirus Infection (1) Coronavirus Infections / therapy (1) Coronavirus Virus Diseases (1) Covid 19 (1) Covid-19 CTL (1) Covid19 Vaccine (1) Covigenix VAX-001 (1) Critically ill COVID-19 patients (1) EGF (1) Endosomal toll-like receptor 3 (1) EpiVacCorona (1) Fibrosis secondary to Covid19 infection (1) Gamaleya (1) Health Workers (1) Healthcare workers (1) Healthy (1) Herpes Zoster (1) Heterologous effects (1) Heterologous prime-boost vaccination (1) Human (1) IFN type1 (1) IFNγ enzyme-linked immune absorbent spot (ELISpot) (1) IN01 vaccine (1) INO-4800 (1) Immunemo (1) Immunemodulation (1) Immunization, Passive (1) Immunoglobulin (1) Immunoglobulin fragments (1) Immunologic Factors (1) Immunology (1) Inactivated SARS-CoV-2 Vaccine (1) Inactivated vaccine (1) Inactive Vaccine (1) Infectiology (1) Infection (1) Innate immune training (1) Interferon Gamma (1) Intranasal Vaccine (1) Intravenous Immunoglobulin (IVIG) (1) Isotretinoin (1) LV-DC vaccine (1) Lentiviral vector (1) Lentiviral vector, Covid-19/aAPC vaccine (1) M-M-R II ® (1) MMR vaccine (1) MMR vaccine, Respiratory failure, (1) MVA (1) Non-specific effects of BCG (1) Pandemics (1) Passive Immunization (1) Phase I (1) Pooled convalescent Plasma (1) QazCovid-in®, vaccine, III phase, efficiency, safety, immunogenicity (1) RNA COVID 19 (1) Randomized controlled (1) Recombinant Novel Coronavirus Vaccine (1) Respiratory disease (1) Retrospective Studies (1) SARS (Severe Acute Respiratory Syndrome) (1) SARS CoV 2 (1) SARS-COV-2 (1) SARS-CoV Infection (1) SARS-CoV-2 (Severe Acute respiratory syndrome Coronavirus 2) (1) SARS-CoV-2-specific serum neutralising antibody titer (1) SARS-CoV-2-surrogate viral neutralising antibody (1) SARS-Cov2 spike protein-binding IgG antibody titer (1) SARS-Cov2 spike protein-specific CD4+ and CD8+ T-cells responses (1) SARS-Cov2 spike protein-specific Th1/Th2 polarisation (1) Sars-Cov-2 Virus Infection (1) Sepsis (1) Severe Acute Respiratory Syndrome (SARS) (1) Severe COVID-19 patients (1) Sputnik (1) Systems Biology (1) T Cells (1) Therapeutic Vaccine (1) Transmission (1) VLA2001 (1) VXA-C0V2-1 (1) Vaccination (1) Vaccinology (1) Vaxart oral vaccine (1) adaptive design (1) adenoviral vector vaccine (1) adenovirus vector (1) adjuvant (1) adult (1) allergy and immunology (1) anti-infective (1) clinical trial (1) corona virus infection (1) coronavirus disease 2019 (1) dendritic cell (1) dose-finding (1) efficacy (1) exploratory efficacy (1) healthy adults (1) healthy elderlies (1) healthy volunteer (1) inactivated vaccine (1) inactivated-adjuvanted Sars-Cov-2 virus vaccine (1) infection (1) inflammation (1) intravenous immunogloulin therapy (1) live attenuated (1) live attenuated vaccine (1) lung disease (1) myeloid-derived suppressor cells (1) novel lipid nanoparticles (LNPs)-encapsulated mRNA-based vaccine (1) off-target effects (1) pandemic (1) passive immunization (1) pneumonia (1) preemptive (1) prevention (1) prophylaxis (1) rAd26-S (1) reactivity (1) respiratory disease (1) safety (1) self amplifying RNA vaccine (1) tablet vaccine (1) therapeutic vaccine (1) tolerability (1) trained immunity (1) trained innate immunity (1) vaccination (1) vaccine, I/II phase, safety, immunogenicity, QazCovid-in® (1) vector (1)

    RNA COVID 19

    This report considers only clinical trials that are associated with COVID-19 vaccines.

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (8)


    Name (Synonyms) Correlation
    drug103 ARCT-021 single dose priming Wiki 1.00
    drug2504 Placebo (two doses), priming Wiki 1.00
    drug2787 Randomized booster Wiki 1.00
    Name (Synonyms) Correlation
    drug105 ARCT-021 two lower dose priming Wiki 1.00
    drug104 ARCT-021 two higher dose priming Wiki 1.00
    drug2530 Placebo booster Wiki 1.00
    drug157 Ad26.COV2.S Wiki 0.58
    drug2490 Placebo Wiki 0.13

    Correlated MeSH Terms (4)


    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.41
    D007239 Infection NIH 0.24
    D045169 Severe Acute Respiratory Syndrome NIH 0.20
    Name (Synonyms) Correlation
    D018352 Coronavirus Infections NIH 0.16

    Correlated HPO Terms (0)


    Name (Synonyms) Correlation

    Clinical Trials

    Navigate: Correlations   HPO

    There is one clinical trial.


    1 A Phase 2 Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of the SARS CoV-2 Vaccine ARCT-021 in Healthy Adult Participants

    This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older

    NCT04668339
    Conditions
    1. Covid19
    2. SARS-CoV Infection
    3. Corona Virus Infection
    Interventions
    1. Biological: ARCT-021 single dose priming
    2. Biological: ARCT-021 two lower dose priming
    3. Biological: ARCT-021 two higher dose priming
    4. Biological: Placebo (two doses), priming
    5. Biological: Randomized booster
    6. Biological: Placebo booster
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Adverse events reported daily in a diary that reflect common symptoms or findings at the injection site following vaccination

    Measure: Percentages of participants reporting solicited local adverse events

    Time: for 7 days following each dose administration

    Description: Adverse events reported daily in a diary that reflect generalized symptoms following vaccination

    Measure: Percentages of participants reporting solicited systemic adverse events

    Time: for 7 days following each dose administration

    Description: spontaneously reported adverse events

    Measure: Percentages of participants reporting adverse events

    Time: 28 days following each dose administration

    Description: unsolicited adverse events that meet the definition of serious

    Measure: Percentages of participants reporting serious adverse events

    Time: Day 0 to Day 388

    Description: unsolicited adverse events that lead to healthcare provider visit

    Measure: Percentages of participants reporting medically attended adverse events

    Time: Day 0 to Day 388

    Description: unsolicited adverse events associated with new diagnosis of chronic disease

    Measure: Percentages of participants reporting new onset of chronic disease

    Time: Day 0 to Day 388

    Description: chemistry and hematology

    Measure: Percentages of participants with abnormal chemistry and hematology values

    Time: Day 0 to Day 215

    Description: neutralizing antibody response

    Measure: SARS-CoV-2 serum neutralizing antibody levels, expressed as GMTs

    Time: Day 0 to Day 388

    Description: neutralizing antibody response

    Measure: Changes in SARS-CoV-2 serum neutralizing titers from before vaccination to each subsequent time point, expressed as GMFRs

    Time: Through Day 388

    Description: neutralizing antibody response

    Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 serum neutralizing antibody levels

    Time: Through Day 388

    Secondary Outcomes

    Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses

    Measure: SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels, expressed as GMCs

    Time: Day 0 to Day 388

    Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses

    Measure: Changes in SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels from before vaccination to each subsequent time point, expressed as GMFRs

    Time: Through Day 388

    Description: SARS-CoV-2 anti S1, RBD, N binding antibody responses

    Measure: Percentages of participants achieving greater than or equal to 2-fold and 4-fold rises from before vaccination in SARS-CoV-2 SARS-CoV-2 anti-S1, anti-RBD, and anti-N binding antibody levels

    Time: Through Day 388

    No related HPO nodes (Using clinical trials)


    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    No related HPO nodes (Using clinical trials)


    Reports

    Data processed on January 01, 2021.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook